{"entity":{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","aka":["Open lung cancer trials","Lung cancer trials recruiting"],"tldr":"Every phase 2 or 3 interventional trial that was recruiting, about to open or still running for lung cancer on ClinicalTrials.gov in September 2026, with the hospitals in the United Kingdom that take part named where the registry lists them.","summary":"The ClinicalTrials.gov v2 API was searched on 25 September 2026 for interventional phase 2, 1/2, 2/3 and 3 studies naming lung cancer, non-small-cell lung cancer or small-cell lung cancer that were recruiting, not yet recruiting, enrolling by invitation or (for phase 3 and 2/3) active but closed to recruitment. That returned 1,948 unique studies; the 766 already in the corpus, and the studies whose only lung involvement is a metastasis from another primary or a thymic or pleural tumour, were removed, leaving 1,075 new to the corpus.\n\nLung cancer has more open phase 2 trials than any other cancer, and most of them are single-centre investigator-initiated studies in one country that will never report outside a local journal. So a breadth rule is applied: every phase 3 and 2/3 trial is kept, and a phase 2 or 1/2 trial is kept only when it has an industry sponsor or collaborator, a site in the United Kingdom, or sites in three or more countries. That leaves 323 records, 146 of them phase 3 and 27 phase 2/3, carried with no outcomes, because a trial that has not reported has no result to quote.\n\nRecords link to the page the registry text names, so a trial of an EGFR inhibitor lands on the EGFR-mutant page and a trial of consolidation radiotherapy on the stage III page, and to `lung-cancer` itself only when the registry names nothing more specific. UK sites are quoted verbatim in each record's notes. Of the 1,075 trials new to the corpus, China ran 435 and the United States 271, and only eleven listed a United Kingdom site, which is a measure of how much of the current lung cancer question is being asked elsewhere.\n\nThe questions open today divide into five: whether antibody-drug conjugates can displace chemotherapy after immunotherapy fails, whether bispecific antibodies against PD-1 and VEGF beat pembrolizumab in the first line, what to do after osimertinib, whether DLL3 engagers move from third line to first in small-cell disease, and whether perioperative immunotherapy should be given before surgery, after it, or both.","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov search: lung cancer, interventional, phase 2 and 3","url":"https://clinicaltrials.gov/search?cond=lung%20cancer&aggFilters=phase:2%203,studyType:int"}],"tags":[],"related":[],"cancers":["lung-cancer"],"sections":[],"technologies":["checkpoint-inhibitor","kinase-inhibitors","adc","bispecific-antibody","t-cell-engager"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["driver-mutation","pd-l1-testing","neoadjuvant-adjuvant"],"trials":["nct04695925","nct06031558","nct05943795","nct03811002","nct06872541","nct01993810","nct03391869","nct03774732","nct04597671","nct07076693","nct04804644","nct04536675","nct04929041","nct06632327","nct04214262","nct05096663","nct04547504","nct04155034","nct03637816","nct04093167","nct04564157","nct06505837","nct03977194","nct03793179","nct04841811","nct04092283","nct06732401","nct06500455","nct06281964","nct06370416","nct06759857","nct04762459","nct06419179","nct07710612","nct07355231","nct07796100","nct07477808","nct07234877","nct07169903","nct05496166","nct05186506","nct07637513","nct07285148","nct07742956","nct07063329","nct06970782","nct07360132","nct07289646","nct05859217","nct07739199","nct07808138","nct07501169","nct05764928","nct07704645","nct05767892","nct04153734","nct06526624","nct06908772","nct07718737","nct06456138","nct06847334","nct07798947","nct06045767","nct07560358","nct07076095","nct07256509","nct06955325","nct07416058","nct07135882","nct07402070","nct07545213","nct07723482","nct07318883","nct07739966","nct06581380","nct07728955","nct07242274","nct06672068","nct07453394","nct06683703","nct07633873","nct07816380","nct06704620","nct06469879","nct07343479","nct07162883","nct06961188","nct06319313","nct07383116","nct07158840","nct07551635","nct07146230","nct07551414","nct07819591","nct07636226","nct07739186","nct07101627","nct07829549","nct07819578","nct06323148","nct04846634","nct06780839","nct07680790","nct07802821","nct07802834","nct07603791","nct06028633","nct07450183","nct01394679","nct07707895","nct07608159","nct07754123","nct07746388","nct06858410","nct05745740","nct04465968","nct06198907","nct07283198","nct07756645","nct07688577","nct07154368","nct05393466","nct06961201","nct07821684","nct06102161","nct06775483","nct05503888","nct07043907","nct06380348","nct07827261","nct06416852","nct06951399","nct05990127","nct07617389","nct07464327","nct07294261","nct07414927","nct07472647","nct07106528","nct06719336","nct07197853","nct07831863","nct07442565","nct06982924","nct07806773","nct06048315","nct07609251","nct07361484","nct06254599","nct07672223","nct06885840","nct07833202","nct06525350","nct07538271","nct07376382","nct07229339","nct04772287","nct06335355","nct07160686","nct07554859","nct07715396","nct07824882","nct07822542","nct07150416","nct06828757","nct07662811","nct07323641","nct05085028","nct07057791","nct06315010","nct05825443","nct07153055","nct07034326","nct05607108","nct07149363","nct04691817","nct07559929","nct06478108","nct06814496","nct05718323","nct06177925","nct05903092","nct07149649","nct07132190","nct07219576","nct01639508","nct04585490","nct06284317","nct07251582","nct07535463","nct06616584","nct05852990","nct07213375","nct06674343","nct05469022","nct05624996","nct06110572","nct06698965","nct06663098","nct05987644","nct05623319","nct05450965","nct06931717","nct05918302","nct06810375","nct05692999","nct07718243","nct06498635","nct05502913","nct05950139","nct04335292","nct02468024","nct05445791","nct06686771","nct06623656","nct06987734","nct07339059","nct06864624","nct04499053","nct05623267","nct06457906","nct07355205","nct06230445","nct05522660","nct04339218","nct06908993","nct04317534","nct07001618","nct07423585","nct05055908","nct06043973","nct05632809","nct07481786","nct06840782","nct07428044","nct07443397","nct07016126","nct04875585","nct06448572","nct06634966","nct04871412","nct06290869","nct06500481","nct05570825","nct05236946","nct06865339","nct05800223","nct05501665","nct06523673","nct06031181","nct06248606","nct06822543","nct07133425","nct06475209","nct04267848","nct05286957","nct07602855","nct05429463","nct07224152","nct07485452","nct05255302","nct04410796","nct06607796","nct06096844","nct05588388","nct07131319","nct06102057","nct06610734","nct04322617","nct04966663","nct07052669","nct07388524","nct06031246","nct06338683","nct07050043","nct06222489","nct07535437","nct07809256","nct07058519","nct05334277","nct06840704","nct06951646","nct04980716","nct07008716","nct05278052","nct07016230","nct06851663","nct06449313","nct07554846","nct07198841","nct06545747","nct06127654","nct06437977","nct07738172","nct06734702","nct07110103","nct07155200","nct05578326","nct07412262","nct06401824","nct06745882","nct07322341","nct06784791","nct06634056","nct04181060","nct07405190","nct04829708","nct04933903","nct07203053","nct06598527","nct07655622","nct07492342","nct06431633","nct02448992","nct07815223","nct04273061","nct06121505","nct04919382","nct06141070","nct07015892","nct05717803","nct06672133","nct06441344"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Trials"},"route":"/terms/lung-trials-open-today/","neighbours":{"cancer":[{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"term":[{"id":"driver-mutation","kind":"term","name":"Driver mutation","route":"/terms/driver-mutation/"},{"id":"neoadjuvant-adjuvant","kind":"term","name":"Neoadjuvant / adjuvant / perioperative","route":"/terms/neoadjuvant-adjuvant/"},{"id":"pd-l1-testing","kind":"term","name":"PD-L1 expression testing (22C3, SP142, SP263)","route":"/terms/pd-l1-testing/"}],"trial":[{"id":"nct07414927","kind":"trial","name":"A Clinical Study for the Efficacy and Safety of BL0020 Injection in Patients With Small Cell Lung Cancer Transformed From Non-Small Cell Lung Cancer Following E","route":"/trials/nct07414927/"},{"id":"nct07609251","kind":"trial","name":"A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study","route":"/trials/nct07609251/"},{"id":"nct05943795","kind":"trial","name":"A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma","route":"/trials/nct05943795/"},{"id":"nct06469879","kind":"trial","name":"A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients","route":"/trials/nct06469879/"},{"id":"nct06982924","kind":"trial","name":"A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.","route":"/trials/nct06982924/"},{"id":"nct06931717","kind":"trial","name":"A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Re","route":"/trials/nct06931717/"},{"id":"nct07133425","kind":"trial","name":"A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer","route":"/trials/nct07133425/"},{"id":"nct07710612","kind":"trial","name":"A Phase 2 Study of ABSK043 Combined With Osimertinib","route":"/trials/nct07710612/"},{"id":"nct01394679","kind":"trial","name":"A Phase 3 Study of 99mTC-EC-DG SPECT/CT Versus PET/CT in Lung Cancer","route":"/trials/nct01394679/"},{"id":"nct07833202","kind":"trial","name":"A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutatio","route":"/trials/nct07833202/"},{"id":"nct06177925","kind":"trial","name":"A Phase II Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC","route":"/trials/nct06177925/"},{"id":"nct07798947","kind":"trial","name":"A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC","route":"/trials/nct07798947/"},{"id":"nct07283198","kind":"trial","name":"A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer","route":"/trials/nct07283198/"},{"id":"nct07824882","kind":"trial","name":"A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamo","route":"/trials/nct07824882/"},{"id":"nct07815223","kind":"trial","name":"A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC","route":"/trials/nct07815223/"},{"id":"nct07318883","kind":"trial","name":"A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab","route":"/trials/nct07318883/"},{"id":"nct06335355","kind":"trial","name":"A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients","route":"/trials/nct06335355/"},{"id":"nct07076095","kind":"trial","name":"A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer","route":"/trials/nct07076095/"},{"id":"nct07376382","kind":"trial","name":"A Phase III Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC","route":"/trials/nct07376382/"},{"id":"nct07464327","kind":"trial","name":"A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-S","route":"/trials/nct07464327/"},{"id":"nct07816380","kind":"trial","name":"A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer","route":"/trials/nct07816380/"},{"id":"nct07101627","kind":"trial","name":"A Prospective, Multicenter Clinical Study of Hetrombopag in the Prevention of Thrombocytopenia Caused by Lung Cancer Therapy","route":"/trials/nct07101627/"},{"id":"nct07809256","kind":"trial","name":"A Prospective, Single-center, Non-randomized, Interventional Study on the Effectiveness and Safety of Combined Immunotargeted Therapy in Patients With Metastati","route":"/trials/nct07809256/"},{"id":"nct05085028","kind":"trial","name":"A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung","route":"/trials/nct05085028/"},{"id":"nct06822543","kind":"trial","name":"A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cance","route":"/trials/nct06822543/"},{"id":"nct06048315","kind":"trial","name":"A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs W","route":"/trials/nct06048315/"},{"id":"nct07728955","kind":"trial","name":"A Single-arm, Exploratory Clinical Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Anlotinib and Etoposide as First-line Therapy for","route":"/trials/nct07728955/"},{"id":"nct07739199","kind":"trial","name":"A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line","route":"/trials/nct07739199/"},{"id":"nct05186506","kind":"trial","name":"A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer","route":"/trials/nct05186506/"},{"id":"nct07802821","kind":"trial","name":"A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Sm","route":"/trials/nct07802821/"},{"id":"nct07739186","kind":"trial","name":"A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment f","route":"/trials/nct07739186/"},{"id":"nct07822542","kind":"trial","name":"A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Pat","route":"/trials/nct07822542/"},{"id":"nct07831863","kind":"trial","name":"A Study of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior Chemoimmunotherapy","route":"/trials/nct07831863/"},{"id":"nct05990127","kind":"trial","name":"A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer","route":"/trials/nct05990127/"},{"id":"nct07538271","kind":"trial","name":"A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer","route":"/trials/nct07538271/"},{"id":"nct07827261","kind":"trial","name":"A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer","route":"/trials/nct07827261/"},{"id":"nct07412262","kind":"trial","name":"A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and Hig","route":"/trials/nct07412262/"},{"id":"nct05859217","kind":"trial","name":"A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)","route":"/trials/nct05859217/"},{"id":"nct07739966","kind":"trial","name":"A Study of DS-3939a in Participants With Solid Tumors","route":"/trials/nct07739966/"},{"id":"nct07559929","kind":"trial","name":"A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.","route":"/trials/nct07559929/"},{"id":"nct06526624","kind":"trial","name":"A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer","route":"/trials/nct06526624/"},{"id":"nct07535437","kind":"trial","name":"A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer","route":"/trials/nct07535437/"},{"id":"nct07535463","kind":"trial","name":"A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer","route":"/trials/nct07535463/"},{"id":"nct07058519","kind":"trial","name":"A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC","route":"/trials/nct07058519/"},{"id":"nct05745740","kind":"trial","name":"A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation","route":"/trials/nct05745740/"},{"id":"nct07602855","kind":"trial","name":"A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)","route":"/trials/nct07602855/"},{"id":"nct06254599","kind":"trial","name":"A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC","route":"/trials/nct06254599/"},{"id":"nct07256509","kind":"trial","name":"A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous No","route":"/trials/nct07256509/"},{"id":"nct07672223","kind":"trial","name":"A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)","route":"/trials/nct07672223/"},{"id":"nct07428044","kind":"trial","name":"A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer","route":"/trials/nct07428044/"},{"id":"nct06672068","kind":"trial","name":"A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC","route":"/trials/nct06672068/"},{"id":"nct05607108","kind":"trial","name":"A Study of ZEN003694 in People With Squamous Cell Lung Cancer","route":"/trials/nct05607108/"},{"id":"nct07796100","kind":"trial","name":"A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Ther","route":"/trials/nct07796100/"},{"id":"nct07821684","kind":"trial","name":"A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanc","route":"/trials/nct07821684/"},{"id":"nct07756645","kind":"trial","name":"A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advan","route":"/trials/nct07756645/"},{"id":"nct06847334","kind":"trial","name":"A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX17 Vs. Keytruda® in the First-Line Treatment of Advanced Non-squamous","route":"/trials/nct06847334/"},{"id":"nct07285148","kind":"trial","name":"A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer","route":"/trials/nct07285148/"},{"id":"nct06284317","kind":"trial","name":"A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Canc","route":"/trials/nct06284317/"},{"id":"nct06525350","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed","route":"/trials/nct06525350/"},{"id":"nct07203053","kind":"trial","name":"A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2","route":"/trials/nct07203053/"},{"id":"nct06248606","kind":"trial","name":"Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases","route":"/trials/nct06248606/"},{"id":"nct07746388","kind":"trial","name":"Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial","route":"/trials/nct07746388/"},{"id":"nct06545747","kind":"trial","name":"Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI","route":"/trials/nct06545747/"},{"id":"nct06616584","kind":"trial","name":"Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemoth","route":"/trials/nct06616584/"},{"id":"nct06141070","kind":"trial","name":"Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease","route":"/trials/nct06141070/"},{"id":"nct07715396","kind":"trial","name":"Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden","route":"/trials/nct07715396/"},{"id":"nct06719336","kind":"trial","name":"Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001)","route":"/trials/nct06719336/"},{"id":"nct06475209","kind":"trial","name":"Adebrelimab + Apatinib in SCLC Maintenance Therapy","route":"/trials/nct06475209/"},{"id":"nct07560358","kind":"trial","name":"Adebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III Unresectable Non-Small Cell Lung Cancer","route":"/trials/nct07560358/"},{"id":"nct06672133","kind":"trial","name":"Adebrelimab Combined with Chemotherapy and Thoracic Radiotherapy for First-line Treatment of ES-SCLC","route":"/trials/nct06672133/"},{"id":"nct07149363","kind":"trial","name":"Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer","route":"/trials/nct07149363/"},{"id":"nct05825443","kind":"trial","name":"Adjuvant Chemotherapy Combined With Camrelizumab for IIA -IIIA NSCLC Patients","route":"/trials/nct05825443/"},{"id":"nct07802834","kind":"trial","name":"Adjuvant ctDNA-Adapted Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLC","route":"/trials/nct07802834/"},{"id":"nct04317534","kind":"trial","name":"Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm","route":"/trials/nct04317534/"},{"id":"nct06323148","kind":"trial","name":"Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)","route":"/trials/nct06323148/"},{"id":"nct04772287","kind":"trial","name":"Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)","route":"/trials/nct04772287/"},{"id":"nct06780839","kind":"trial","name":"Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD","route":"/trials/nct06780839/"},{"id":"nct07158840","kind":"trial","name":"AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor","route":"/trials/nct07158840/"},{"id":"nct06043973","kind":"trial","name":"Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance","route":"/trials/nct06043973/"},{"id":"nct03637816","kind":"trial","name":"Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer","route":"/trials/nct03637816/"},{"id":"nct04322617","kind":"trial","name":"Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer","route":"/trials/nct04322617/"},{"id":"nct07443397","kind":"trial","name":"Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.","route":"/trials/nct07443397/"},{"id":"nct07160686","kind":"trial","name":"Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment","route":"/trials/nct07160686/"},{"id":"nct05800223","kind":"trial","name":"Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer","route":"/trials/nct05800223/"},{"id":"nct06663098","kind":"trial","name":"Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).","route":"/trials/nct06663098/"},{"id":"nct03977194","kind":"trial","name":"Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy","route":"/trials/nct03977194/"},{"id":"nct07481786","kind":"trial","name":"Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases","route":"/trials/nct07481786/"},{"id":"nct07485452","kind":"trial","name":"Boosting Osimertinib Blood Brain Barrier Penetration","route":"/trials/nct07485452/"},{"id":"nct05393466","kind":"trial","name":"BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct05393466/"},{"id":"nct04933903","kind":"trial","name":"BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab","route":"/trials/nct04933903/"},{"id":"nct01639508","kind":"trial","name":"Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or A","route":"/trials/nct01639508/"},{"id":"nct06096844","kind":"trial","name":"Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial","route":"/trials/nct06096844/"},{"id":"nct07197853","kind":"trial","name":"Clinical Efficacy and Safety of Microwave Ablation Combined With Huaier Granules in Patients With Inoperable Stage IA Non-Small Cell Lung Cancer: A Prospective,","route":"/trials/nct07197853/"},{"id":"nct06416852","kind":"trial","name":"Clinical Study of 18F-Alfatide Injection PET/CT","route":"/trials/nct06416852/"},{"id":"nct06828757","kind":"trial","name":"Clinical Study of Nanocrystalline Megestrol in Malnourished Patients With First-Line Non-Small Cell Lung Cancer","route":"/trials/nct06828757/"},{"id":"nct06961188","kind":"trial","name":"Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis","route":"/trials/nct06961188/"},{"id":"nct06632327","kind":"trial","name":"Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer","route":"/trials/nct06632327/"},{"id":"nct01993810","kind":"trial","name":"Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer","route":"/trials/nct01993810/"},{"id":"nct07554846","kind":"trial","name":"Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC","route":"/trials/nct07554846/"},{"id":"nct04339218","kind":"trial","name":"Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma","route":"/trials/nct04339218/"},{"id":"nct06951646","kind":"trial","name":"ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)","route":"/trials/nct06951646/"},{"id":"nct07016126","kind":"trial","name":"D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC","route":"/trials/nct07016126/"},{"id":"nct07707895","kind":"trial","name":"DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers","route":"/trials/nct07707895/"},{"id":"nct05255302","kind":"trial","name":"De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction","route":"/trials/nct05255302/"},{"id":"nct05987644","kind":"trial","name":"Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements","route":"/trials/nct05987644/"},{"id":"nct07361484","kind":"trial","name":"Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)","route":"/trials/nct07361484/"},{"id":"nct07015892","kind":"trial","name":"Dose-Escalation Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized Trial","route":"/trials/nct07015892/"},{"id":"nct04597671","kind":"trial","name":"Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28)","route":"/trials/nct04597671/"},{"id":"nct04499053","kind":"trial","name":"Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer","route":"/trials/nct04499053/"},{"id":"nct04980716","kind":"trial","name":"Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients","route":"/trials/nct04980716/"},{"id":"nct07251582","kind":"trial","name":"Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer","route":"/trials/nct07251582/"},{"id":"nct04536675","kind":"trial","name":"Effect of Perioperative Bronchodilator in COPD Patients Undergoing Lung Cancer Surgery","route":"/trials/nct04536675/"},{"id":"nct06230445","kind":"trial","name":"Effects of Digital Therapeutic in Whole Process Management of Lung Cancer","route":"/trials/nct06230445/"},{"id":"nct05055908","kind":"trial","name":"Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors","route":"/trials/nct05055908/"},{"id":"nct06281964","kind":"trial","name":"Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.","route":"/trials/nct06281964/"},{"id":"nct04762459","kind":"trial","name":"Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Com","route":"/trials/nct04762459/"},{"id":"nct04465968","kind":"trial","name":"Efficacy and Safety of CRT, Durvalumab and Surgery for SST","route":"/trials/nct04465968/"},{"id":"nct06698965","kind":"trial","name":"Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and C","route":"/trials/nct06698965/"},{"id":"nct06607796","kind":"trial","name":"Efficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy","route":"/trials/nct06607796/"},{"id":"nct06319313","kind":"trial","name":"Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer","route":"/trials/nct06319313/"},{"id":"nct06028633","kind":"trial","name":"Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients","route":"/trials/nct06028633/"},{"id":"nct04829708","kind":"trial","name":"Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cell Lung Cancer Who Achieved Remission Aft","route":"/trials/nct04829708/"},{"id":"nct05918302","kind":"trial","name":"Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.","route":"/trials/nct05918302/"},{"id":"nct07545213","kind":"trial","name":"Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis","route":"/trials/nct07545213/"},{"id":"nct07034326","kind":"trial","name":"Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung Cancer","route":"/trials/nct07034326/"},{"id":"nct06810375","kind":"trial","name":"Erector Spinae Versus Intercostal Nerve Blocks With Liposomal Bupivacaine for Analgesia in Thoracic Surgery","route":"/trials/nct06810375/"},{"id":"nct05764928","kind":"trial","name":"Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Pemetrexed + Cisplatin Therapy","route":"/trials/nct05764928/"},{"id":"nct06775483","kind":"trial","name":"Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study","route":"/trials/nct06775483/"},{"id":"nct06872541","kind":"trial","name":"Evaluation of Platelet Aggregability in Patients with Non-small Cell Lung Carcinomas","route":"/trials/nct06872541/"},{"id":"nct06448572","kind":"trial","name":"EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy.","route":"/trials/nct06448572/"},{"id":"nct05502913","kind":"trial","name":"Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer","route":"/trials/nct05502913/"},{"id":"nct06759857","kind":"trial","name":"FHND9041 Versus Afatinib for Non-small Cell Lung Cancer","route":"/trials/nct06759857/"},{"id":"nct06840782","kind":"trial","name":"First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.","route":"/trials/nct06840782/"},{"id":"nct07355205","kind":"trial","name":"First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer","route":"/trials/nct07355205/"},{"id":"nct07492342","kind":"trial","name":"Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC","route":"/trials/nct07492342/"},{"id":"nct07289646","kind":"trial","name":"Functional Lung Avoidance Planning Guided by Lung Perfusion PET/CT Versus Anatomical Planning for Lung Stereotactic Body Radiotherapy","route":"/trials/nct07289646/"},{"id":"nct06674343","kind":"trial","name":"Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations","route":"/trials/nct06674343/"},{"id":"nct05334277","kind":"trial","name":"Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA","route":"/trials/nct05334277/"},{"id":"nct07294261","kind":"trial","name":"Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC","route":"/trials/nct07294261/"},{"id":"nct07554859","kind":"trial","name":"GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer","route":"/trials/nct07554859/"},{"id":"nct07718737","kind":"trial","name":"Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Can","route":"/trials/nct07718737/"},{"id":"nct06908772","kind":"trial","name":"Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients","route":"/trials/nct06908772/"},{"id":"nct05852990","kind":"trial","name":"Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC","route":"/trials/nct05852990/"},{"id":"nct06198907","kind":"trial","name":"Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)","route":"/trials/nct06198907/"},{"id":"nct07110103","kind":"trial","name":"Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC","route":"/trials/nct07110103/"},{"id":"nct07213375","kind":"trial","name":"High Dose Dexamethasone to Reduce Postoperative Pain After Video-Assisted Thoracoscopic Surgery Lobectomy /Segmentectomy","route":"/trials/nct07213375/"},{"id":"nct02448992","kind":"trial","name":"Hippocampal-Sparing Prophylactic Cranial Irradiation in Pathologically Nodal Positive Non-Small-Cell Lung Cancer","route":"/trials/nct02448992/"},{"id":"nct07052669","kind":"trial","name":"Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC","route":"/trials/nct07052669/"},{"id":"nct07198841","kind":"trial","name":"IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation","route":"/trials/nct07198841/"},{"id":"nct07402070","kind":"trial","name":"IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer","route":"/trials/nct07402070/"},{"id":"nct06840704","kind":"trial","name":"Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer","route":"/trials/nct06840704/"},{"id":"nct06498635","kind":"trial","name":"Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial","route":"/trials/nct06498635/"},{"id":"nct05522660","kind":"trial","name":"Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer","route":"/trials/nct05522660/"},{"id":"nct06478108","kind":"trial","name":"Interventional Software for Multi-immunotherapy of Solid Tumors","route":"/trials/nct06478108/"},{"id":"nct07718243","kind":"trial","name":"Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC","route":"/trials/nct07718243/"},{"id":"nct04273061","kind":"trial","name":"Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity","route":"/trials/nct04273061/"},{"id":"nct07405190","kind":"trial","name":"Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC","route":"/trials/nct07405190/"},{"id":"nct06581380","kind":"trial","name":"JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer","route":"/trials/nct06581380/"},{"id":"nct06380348","kind":"trial","name":"JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Chara","route":"/trials/nct06380348/"},{"id":"nct02468024","kind":"trial","name":"JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer","route":"/trials/nct02468024/"},{"id":"nct06505837","kind":"trial","name":"JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC）","route":"/trials/nct06505837/"},{"id":"nct07154368","kind":"trial","name":"JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs.","route":"/trials/nct07154368/"},{"id":"nct06858410","kind":"trial","name":"Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma","route":"/trials/nct06858410/"},{"id":"nct07050043","kind":"trial","name":"Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC","route":"/trials/nct07050043/"},{"id":"nct07355231","kind":"trial","name":"Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRI","route":"/trials/nct07355231/"},{"id":"nct07153055","kind":"trial","name":"Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer","route":"/trials/nct07153055/"},{"id":"nct07149649","kind":"trial","name":"Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)","route":"/trials/nct07149649/"},{"id":"nct06419179","kind":"trial","name":"Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extens","route":"/trials/nct06419179/"},{"id":"nct05692999","kind":"trial","name":"Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study","route":"/trials/nct05692999/"},{"id":"nct04841811","kind":"trial","name":"MDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+ Unresectable Stage III NSCLC (APPROACH)","route":"/trials/nct04841811/"},{"id":"nct07477808","kind":"trial","name":"Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer","route":"/trials/nct07477808/"},{"id":"nct05445791","kind":"trial","name":"Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations","route":"/trials/nct05445791/"},{"id":"nct07723482","kind":"trial","name":"ML-016 in Advanced Cancer With Lung and/or Liver Involvement","route":"/trials/nct07723482/"},{"id":"nct05903092","kind":"trial","name":"MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer","route":"/trials/nct05903092/"},{"id":"nct05286957","kind":"trial","name":"MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC","route":"/trials/nct05286957/"},{"id":"nct06610734","kind":"trial","name":"Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Ext","route":"/trials/nct06610734/"},{"id":"nct06961201","kind":"trial","name":"Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cache","route":"/trials/nct06961201/"},{"id":"nct07224152","kind":"trial","name":"NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer","route":"/trials/nct07224152/"},{"id":"nct07150416","kind":"trial","name":"Nebulized Inhalation of Recombinant Human p53 Adenovirus Injection for Treatment of Multiple Ground-Glass Lung Nodules: A Single-Arm Clinical Study","route":"/trials/nct07150416/"},{"id":"nct06449313","kind":"trial","name":"Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features","route":"/trials/nct06449313/"},{"id":"nct06734702","kind":"trial","name":"Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Ca","route":"/trials/nct06734702/"},{"id":"nct05469022","kind":"trial","name":"Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy","route":"/trials/nct05469022/"},{"id":"nct07608159","kind":"trial","name":"Neoadjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC.","route":"/trials/nct07608159/"},{"id":"nct06987734","kind":"trial","name":"Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients","route":"/trials/nct06987734/"},{"id":"nct06437977","kind":"trial","name":"Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH)","route":"/trials/nct06437977/"},{"id":"nct05429463","kind":"trial","name":"Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE II）","route":"/trials/nct05429463/"},{"id":"nct04564157","kind":"trial","name":"New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy","route":"/trials/nct04564157/"},{"id":"nct05718323","kind":"trial","name":"Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC","route":"/trials/nct05718323/"},{"id":"nct03391869","kind":"trial","name":"Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer","route":"/trials/nct03391869/"},{"id":"nct05236946","kind":"trial","name":"Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT","route":"/trials/nct05236946/"},{"id":"nct07008716","kind":"trial","name":"Omitting CTV for Primary Tumor in LS-SCLC","route":"/trials/nct07008716/"},{"id":"nct07001618","kind":"trial","name":"Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiot","route":"/trials/nct07001618/"},{"id":"nct07106528","kind":"trial","name":"Organoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung Cancer","route":"/trials/nct07106528/"},{"id":"nct04410796","kind":"trial","name":"Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers","route":"/trials/nct04410796/"},{"id":"nct04695925","kind":"trial","name":"Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations","route":"/trials/nct04695925/"},{"id":"nct04335292","kind":"trial","name":"Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge","route":"/trials/nct04335292/"},{"id":"nct04181060","kind":"trial","name":"Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer","route":"/trials/nct04181060/"},{"id":"nct07738172","kind":"trial","name":"Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung Cancer","route":"/trials/nct07738172/"},{"id":"nct06102057","kind":"trial","name":"PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC","route":"/trials/nct06102057/"},{"id":"nct07819591","kind":"trial","name":"Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC","route":"/trials/nct07819591/"},{"id":"nct07043907","kind":"trial","name":"PANK-003 Cell Injection Combined With Standard Adjuvant Chemotherapy After Surgery in Patients With Stage IIIA NSCLC","route":"/trials/nct07043907/"},{"id":"nct03774732","kind":"trial","name":"PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer","route":"/trials/nct03774732/"},{"id":"nct04153734","kind":"trial","name":"Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC","route":"/trials/nct04153734/"},{"id":"nct05623319","kind":"trial","name":"Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)","route":"/trials/nct05623319/"},{"id":"nct04547504","kind":"trial","name":"PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %","route":"/trials/nct04547504/"},{"id":"nct04846634","kind":"trial","name":"Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (A","route":"/trials/nct04846634/"},{"id":"nct05950139","kind":"trial","name":"Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC","route":"/trials/nct05950139/"},{"id":"nct07450183","kind":"trial","name":"Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1","route":"/trials/nct07450183/"},{"id":"nct06864624","kind":"trial","name":"Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC","route":"/trials/nct06864624/"},{"id":"nct04585490","kind":"trial","name":"Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC","route":"/trials/nct04585490/"},{"id":"nct07162883","kind":"trial","name":"Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct07162883/"},{"id":"nct07242274","kind":"trial","name":"Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC","route":"/trials/nct07242274/"},{"id":"nct07063329","kind":"trial","name":"Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive","route":"/trials/nct07063329/"},{"id":"nct06110572","kind":"trial","name":"Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation","route":"/trials/nct06110572/"},{"id":"nct05503888","kind":"trial","name":"Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer","route":"/trials/nct05503888/"},{"id":"nct07742956","kind":"trial","name":"Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK201 for Injection in Combination With Ivonescimab In","route":"/trials/nct07742956/"},{"id":"nct07603791","kind":"trial","name":"Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC","route":"/trials/nct07603791/"},{"id":"nct07057791","kind":"trial","name":"Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer","route":"/trials/nct07057791/"},{"id":"nct07234877","kind":"trial","name":"Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets","route":"/trials/nct07234877/"},{"id":"nct06121505","kind":"trial","name":"Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer","route":"/trials/nct06121505/"},{"id":"nct07360132","kind":"trial","name":"Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous","route":"/trials/nct07360132/"},{"id":"nct07383116","kind":"trial","name":"Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous No","route":"/trials/nct07383116/"},{"id":"nct07754123","kind":"trial","name":"Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLC","route":"/trials/nct07754123/"},{"id":"nct07829549","kind":"trial","name":"Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Act","route":"/trials/nct07829549/"},{"id":"nct06031558","kind":"trial","name":"Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC","route":"/trials/nct06031558/"},{"id":"nct07416058","kind":"trial","name":"PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC","route":"/trials/nct07416058/"},{"id":"nct06634056","kind":"trial","name":"Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation","route":"/trials/nct06634056/"},{"id":"nct06784791","kind":"trial","name":"Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mut","route":"/trials/nct06784791/"},{"id":"nct06623656","kind":"trial","name":"Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC","route":"/trials/nct06623656/"},{"id":"nct07135882","kind":"trial","name":"Primary Radiotherapy In MEtastatic Lung Cancer","route":"/trials/nct07135882/"},{"id":"nct06745882","kind":"trial","name":"Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC","route":"/trials/nct06745882/"},{"id":"nct07636226","kind":"trial","name":"QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer","route":"/trials/nct07636226/"},{"id":"nct07453394","kind":"trial","name":"QLS5132 Combination Therapy in Advanced Solid Tumors","route":"/trials/nct07453394/"},{"id":"nct06814496","kind":"trial","name":"Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors","route":"/trials/nct06814496/"},{"id":"nct07808138","kind":"trial","name":"RADICAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly InOperable Stage I Non-small Cell Lung Cancer","route":"/trials/nct07808138/"},{"id":"nct06686771","kind":"trial","name":"Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer","route":"/trials/nct06686771/"},{"id":"nct06315010","kind":"trial","name":"Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis","route":"/trials/nct06315010/"},{"id":"nct05632809","kind":"trial","name":"REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)","route":"/trials/nct05632809/"},{"id":"nct07219576","kind":"trial","name":"Retifanlimab and Ruxolitinib In Solid Malignancies","route":"/trials/nct07219576/"},{"id":"nct04155034","kind":"trial","name":"S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cel","route":"/trials/nct04155034/"},{"id":"nct06401824","kind":"trial","name":"Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases","route":"/trials/nct06401824/"},{"id":"nct07501169","kind":"trial","name":"Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)","route":"/trials/nct07501169/"},{"id":"nct07343479","kind":"trial","name":"Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases","route":"/trials/nct07343479/"},{"id":"nct05717803","kind":"trial","name":"Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012)","route":"/trials/nct05717803/"},{"id":"nct06634966","kind":"trial","name":"Segmentectomy for Solid-dominant Lung Cancer","route":"/trials/nct06634966/"},{"id":"nct07169903","kind":"trial","name":"Segmentectomy vs Lobectomy for 2 - 3cm IASLC Grade 1-2 Lung Adenocarcinoma: A Multi-center RCT","route":"/trials/nct07169903/"},{"id":"nct06031246","kind":"trial","name":"Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1018)","route":"/trials/nct06031246/"},{"id":"nct07617389","kind":"trial","name":"Selective Mediastinal Lymph Node Sampling Versus Systematic medIastinal Lymph Node Dissection After Neoadjuvant Chemoimmunotherapy for Non-small Cell Lung Cance","route":"/trials/nct07617389/"},{"id":"nct07131319","kind":"trial","name":"SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC","route":"/trials/nct07131319/"},{"id":"nct07155200","kind":"trial","name":"Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)","route":"/trials/nct07155200/"},{"id":"nct07551635","kind":"trial","name":"SMARCA4/2 Inhibitor for POU2F3-Positive SCLC","route":"/trials/nct07551635/"},{"id":"nct05501665","kind":"trial","name":"Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer","route":"/trials/nct05501665/"},{"id":"nct06457906","kind":"trial","name":"SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC","route":"/trials/nct06457906/"},{"id":"nct05278052","kind":"trial","name":"Standard Maintenance Therapy (SMT) vs Local Consolidative Radiation Therapy and SMT in OM-NSCLC","route":"/trials/nct05278052/"},{"id":"nct07076693","kind":"trial","name":"Standard-of-care Systemic Therapy With or Without Local Therapy in Patients With Oligoprogressive Non-Small Cell Lung Cancer(NSCLC）","route":"/trials/nct07076693/"},{"id":"nct06598527","kind":"trial","name":"Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant The","route":"/trials/nct06598527/"},{"id":"nct06523673","kind":"trial","name":"Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer","route":"/trials/nct06523673/"},{"id":"nct07132190","kind":"trial","name":"Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction","route":"/trials/nct07132190/"},{"id":"nct07016230","kind":"trial","name":"Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocri","route":"/trials/nct07016230/"},{"id":"nct05588388","kind":"trial","name":"Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases","route":"/trials/nct05588388/"},{"id":"nct04093167","kind":"trial","name":"Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer","route":"/trials/nct04093167/"},{"id":"nct07680790","kind":"trial","name":"Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based C","route":"/trials/nct07680790/"},{"id":"nct06885840","kind":"trial","name":"Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.","route":"/trials/nct06885840/"},{"id":"nct05450965","kind":"trial","name":"Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer","route":"/trials/nct05450965/"},{"id":"nct07339059","kind":"trial","name":"Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer","route":"/trials/nct07339059/"},{"id":"nct06704620","kind":"trial","name":"Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Can","route":"/trials/nct06704620/"},{"id":"nct06431633","kind":"trial","name":"Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.","route":"/trials/nct06431633/"},{"id":"nct05578326","kind":"trial","name":"Study of Trilaciclib and Lurbinectidin","route":"/trials/nct05578326/"},{"id":"nct07806773","kind":"trial","name":"Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer","route":"/trials/nct07806773/"},{"id":"nct06031181","kind":"trial","name":"Sublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section (ECTOP-1019)","route":"/trials/nct06031181/"},{"id":"nct05623267","kind":"trial","name":"Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT","route":"/trials/nct05623267/"},{"id":"nct06338683","kind":"trial","name":"Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer","route":"/trials/nct06338683/"},{"id":"nct07322341","kind":"trial","name":"SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer","route":"/trials/nct07322341/"},{"id":"nct05570825","kind":"trial","name":"SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer","route":"/trials/nct05570825/"},{"id":"nct07662811","kind":"trial","name":"SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer","route":"/trials/nct07662811/"},{"id":"nct07633873","kind":"trial","name":"SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNST","route":"/trials/nct07633873/"},{"id":"nct07442565","kind":"trial","name":"SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase III","route":"/trials/nct07442565/"},{"id":"nct07472647","kind":"trial","name":"SYS6090 Combination Therapy in Advanced Lung Cancer","route":"/trials/nct07472647/"},{"id":"nct06045767","kind":"trial","name":"T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer","route":"/trials/nct06045767/"},{"id":"nct07637513","kind":"trial","name":"Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer","route":"/trials/nct07637513/"},{"id":"nct07423585","kind":"trial","name":"Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer","route":"/trials/nct07423585/"},{"id":"nct07323641","kind":"trial","name":"Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer","route":"/trials/nct07323641/"},{"id":"nct04919382","kind":"trial","name":"Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer","route":"/trials/nct04919382/"},{"id":"nct06908993","kind":"trial","name":"Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated","route":"/trials/nct06908993/"},{"id":"nct04804644","kind":"trial","name":"Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of M","route":"/trials/nct04804644/"},{"id":"nct06500455","kind":"trial","name":"Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain","route":"/trials/nct06500455/"},{"id":"nct06500481","kind":"trial","name":"Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial","route":"/trials/nct06500481/"},{"id":"nct03811002","kind":"trial","name":"Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lun","route":"/trials/nct03811002/"},{"id":"nct04267848","kind":"trial","name":"Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Ch","route":"/trials/nct04267848/"},{"id":"nct04092283","kind":"trial","name":"Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Anti","route":"/trials/nct04092283/"},{"id":"nct06732401","kind":"trial","name":"Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer","route":"/trials/nct06732401/"},{"id":"nct05624996","kind":"trial","name":"Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer","route":"/trials/nct05624996/"},{"id":"nct04929041","kind":"trial","name":"Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Pati","route":"/trials/nct04929041/"},{"id":"nct04214262","kind":"trial","name":"Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer","route":"/trials/nct04214262/"},{"id":"nct07388524","kind":"trial","name":"Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial","route":"/trials/nct07388524/"},{"id":"nct03793179","kind":"trial","name":"Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer","route":"/trials/nct03793179/"},{"id":"nct05096663","kind":"trial","name":"Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer","route":"/trials/nct05096663/"},{"id":"nct07704645","kind":"trial","name":"The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer","route":"/trials/nct07704645/"},{"id":"nct05496166","kind":"trial","name":"The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Canc","route":"/trials/nct05496166/"},{"id":"nct06370416","kind":"trial","name":"the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib","route":"/trials/nct06370416/"},{"id":"nct07146230","kind":"trial","name":"The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2","route":"/trials/nct07146230/"},{"id":"nct04871412","kind":"trial","name":"The Thoracic Peri-Operative Integrative Surgical Care Evaluation Trial - Stage III","route":"/trials/nct04871412/"},{"id":"nct06865339","kind":"trial","name":"Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer","route":"/trials/nct06865339/"},{"id":"nct06290869","kind":"trial","name":"Tobacco Education and Lung Health Study (TEAL)","route":"/trials/nct06290869/"},{"id":"nct04691817","kind":"trial","name":"Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based T","route":"/trials/nct04691817/"},{"id":"nct06441344","kind":"trial","name":"Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell","route":"/trials/nct06441344/"},{"id":"nct07819578","kind":"trial","name":"Toripalimab Plus Sacituzumab Tirumotecan as Neoadjuvant Therapy for Resectable NSCLC","route":"/trials/nct07819578/"},{"id":"nct06951399","kind":"trial","name":"Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer","route":"/trials/nct06951399/"},{"id":"nct06456138","kind":"trial","name":"Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC","route":"/trials/nct06456138/"},{"id":"nct04875585","kind":"trial","name":"Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC","route":"/trials/nct04875585/"},{"id":"nct06851663","kind":"trial","name":"Trop2-targeted immunoPET Imaging of Solid Tumors","route":"/trials/nct06851663/"},{"id":"nct06955325","kind":"trial","name":"Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations","route":"/trials/nct06955325/"},{"id":"nct04966663","kind":"trial","name":"Using ctDNA to Determine Therapies for Lung Cancer","route":"/trials/nct04966663/"},{"id":"nct06683703","kind":"trial","name":"Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases","route":"/trials/nct06683703/"},{"id":"nct07655622","kind":"trial","name":"Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression","route":"/trials/nct07655622/"},{"id":"nct06970782","kind":"trial","name":"Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failur","route":"/trials/nct06970782/"},{"id":"nct06127654","kind":"trial","name":"Ventilation Imaging to Improve the Quality of Life for Patients With Lung Cancer Treated With Radiation Therapy","route":"/trials/nct06127654/"},{"id":"nct06102161","kind":"trial","name":"Wedge Resection for Ground-glass Opacity-featured Lung Cancer (ECTOP-1020)","route":"/trials/nct06102161/"},{"id":"nct06222489","kind":"trial","name":"Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT","route":"/trials/nct06222489/"},{"id":"nct07688577","kind":"trial","name":"XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors","route":"/trials/nct07688577/"},{"id":"nct05767892","kind":"trial","name":"YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations","route":"/trials/nct05767892/"},{"id":"nct07229339","kind":"trial","name":"Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer","route":"/trials/nct07229339/"},{"id":"nct07551414","kind":"trial","name":"Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI","route":"/trials/nct07551414/"}]}}